BI
FSTX

BVF Inc’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

BVF Inc’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,844
Closed -$255K – 76
2020
Q4 		$255K Sell
25,844
-209,449
-89% -$1.37M 0.01% 65
2020
Q3 		$1.26M Hold
235,293
– – 0.07% 61
2020
Q2 		$1.38M Sell
235,293
-2,632
-1% -$15.2K 0.09% 53
2020
Q1 		$885K Hold
237,925
– – 0.08% 53
2019
Q4 		$1.5M Sell
237,925
-106,785
-31% -$1.36M 0.11% 53
2019
Q3 		$4.83M Buy
344,710
+19,285
+6% +$318K 0.51% 44
2019
Q2 		$4.8M Buy
325,425
+87,500
+37% +$2.34M 0.52% 44
2019
Q1 		$9.98M Hold
237,925
– – 1.12% 31
2018
Q4 		$9.89M Sell
237,925
-400
-0.2% -$18K 1.29% 26
2018
Q3 		$11.5M Buy
238,325
+41,837
+21% +$2.1M 1.01% 35
2018
Q2 		$9.31M Sell
196,488
-11,574
-6% -$642K 0.91% 31
2018
Q1 		$12.8M Buy
208,062
+2,193
+1% +$116K 1.3% 24
2017
Q4 		$11.1M Buy
205,869
+42,700
+26% +$2.54M 1.34% 24
2017
Q3 		$11M Buy
163,169
+9,323
+6% +$534K 1.4% 22
2017
Q2 		$8.33M Buy
+153,846
New +$7.13M 1.29% 22

Other funds holding FSTX

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc's FSTX Position: Q1 2021 in Review

BVF Inc sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2021, closing a stake of 25,844 shares — an estimated $255K sold.

BVF Inc first reported a position in FSTX in Q2 2017 and held it in 15 quarters. The position peaked at $12.8M in Q1 2018. 26 funds tracked by Wall St. Rank hold FSTX as of Q1 2021.

  • BVF Inc reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • BVF Inc sold 25,844 F-star Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $255K.
  • BVF Inc first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 15 quarters.
  • BVF Inc's F-star Therapeutics, Inc. Common Stock position peaked at $12.8M in Q1 2018.
  • 26 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2021.

Based on BVF Inc's 13F filing for Q1 2021, filed 17 May 2021.